Preptin has been proposed as a potential therapeutic target to improve metabolic dysfunction in individuals with T2DM; however, whether preptin impacted metabolic dysfunction and bone loss associated with a HFD was unknown. The gene discussed is IGF2; the disease is type 2 diabetes mellitus.